View in EDS

Does cefiderocol heteroresistance explain the discrepancy between the APEKS-NP and CREDIBLE-CR clinical trial results?

Saved in:
Bibliographic Details
Title: Does cefiderocol heteroresistance explain the discrepancy between the APEKS-NP and CREDIBLE-CR clinical trial results?
Authors: Choby JE; Emory Antibiotic Resistance Center, Atlanta, GA 30329, USA; Emory Vaccine Center, Atlanta, GA, USA., Ozturk T; Emory Antibiotic Resistance Center, Atlanta, GA 30329, USA; Emory Vaccine Center, Atlanta, GA, USA., Satola SW; Emory Antibiotic Resistance Center, Atlanta, GA 30329, USA; Emory Vaccine Center, Atlanta, GA, USA; Division of Infectious Diseases, Department of Medicine, Emory University School of Medicine, Atlanta, GA, USA; Georgia Emerging Infections Programme, Atlanta, GA, USA., Jacob JT; Emory Antibiotic Resistance Center, Atlanta, GA 30329, USA; Emory Vaccine Center, Atlanta, GA, USA; Division of Infectious Diseases, Department of Medicine, Emory University School of Medicine, Atlanta, GA, USA; Georgia Emerging Infections Programme, Atlanta, GA, USA., Weiss DS; Emory Antibiotic Resistance Center, Atlanta, GA 30329, USA; Emory Vaccine Center, Atlanta, GA, USA; Division of Infectious Diseases, Department of Medicine, Emory University School of Medicine, Atlanta, GA, USA. Electronic address: david.weiss@emory.edu.
Source: The Lancet. Microbe [Lancet Microbe] 2021 Dec; Vol. 2 (12), pp. e648-e649. Date of Electronic Publication: 2021 Oct 28.
Publication Type: Journal Article
Journal Info: Publisher: Elsevier Ltd Country of Publication: England NLM ID: 101769019 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2666-5247 (Electronic) Linking ISSN: 26665247 NLM ISO Abbreviation: Lancet Microbe Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 35544102
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Does cefiderocol heteroresistance explain the discrepancy between the APEKS-NP and CREDIBLE-CR clinical trial results?
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Choby+JE%22">Choby JE</searchLink>; Emory Antibiotic Resistance Center, Atlanta, GA 30329, USA; Emory Vaccine Center, Atlanta, GA, USA.<br /><searchLink fieldCode="AU" term="%22Ozturk+T%22">Ozturk T</searchLink>; Emory Antibiotic Resistance Center, Atlanta, GA 30329, USA; Emory Vaccine Center, Atlanta, GA, USA.<br /><searchLink fieldCode="AU" term="%22Satola+SW%22">Satola SW</searchLink>; Emory Antibiotic Resistance Center, Atlanta, GA 30329, USA; Emory Vaccine Center, Atlanta, GA, USA; Division of Infectious Diseases, Department of Medicine, Emory University School of Medicine, Atlanta, GA, USA; Georgia Emerging Infections Programme, Atlanta, GA, USA.<br /><searchLink fieldCode="AU" term="%22Jacob+JT%22">Jacob JT</searchLink>; Emory Antibiotic Resistance Center, Atlanta, GA 30329, USA; Emory Vaccine Center, Atlanta, GA, USA; Division of Infectious Diseases, Department of Medicine, Emory University School of Medicine, Atlanta, GA, USA; Georgia Emerging Infections Programme, Atlanta, GA, USA.<br /><searchLink fieldCode="AU" term="%22Weiss+DS%22">Weiss DS</searchLink>; Emory Antibiotic Resistance Center, Atlanta, GA 30329, USA; Emory Vaccine Center, Atlanta, GA, USA; Division of Infectious Diseases, Department of Medicine, Emory University School of Medicine, Atlanta, GA, USA. Electronic address: david.weiss@emory.edu.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101769019%22">The Lancet. Microbe</searchLink> [Lancet Microbe] 2021 Dec; Vol. 2 (12), pp. e648-e649. <i>Date of Electronic Publication: </i>2021 Oct 28.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Elsevier+Ltd%22">Elsevier Ltd </searchLink><i>Country of Publication: </i>England <i>NLM ID: </i>101769019 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>2666-5247 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2226665247%22">26665247 </searchLink><i>NLM ISO Abbreviation: </i>Lancet Microbe <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=35544102
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1016/S2666-5247(21)00271-8
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: e648
    Titles:
      – TitleFull: Does cefiderocol heteroresistance explain the discrepancy between the APEKS-NP and CREDIBLE-CR clinical trial results?
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Choby JE
      – PersonEntity:
          Name:
            NameFull: Ozturk T
      – PersonEntity:
          Name:
            NameFull: Satola SW
      – PersonEntity:
          Name:
            NameFull: Jacob JT
      – PersonEntity:
          Name:
            NameFull: Weiss DS
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 12
              Text: 2021 Dec
              Type: published
              Y: 2021
          Identifiers:
            – Type: issn-electronic
              Value: 2666-5247
          Numbering:
            – Type: volume
              Value: 2
            – Type: issue
              Value: 12
          Titles:
            – TitleFull: The Lancet. Microbe
              Type: main
ResultId 1